Head-to-head evidence
Emtricitabine/tenofovir disoproxil fumarate vs Tenofovir alafenamide/emtricitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Emtricitabine/tenofovir disoproxil fumarate · Truvada
Marketed by Gilead Sciences
NCT00323544 · Phase 3 · completed
This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07584122 (registry estimate)
Tenofovir alafenamide/emtricitabine · Descovy
Marketed by Gilead Sciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07349758 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Tenofovir alafenamide/emtricitabine's landscape